In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Madison Inc.

Division of Arrowhead Pharmaceuticals Inc.

Latest From Roche Madison Inc.

Deals Shaping The Medical Industry (12/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Stockwatch: Silence – Nobels and whistles

The 2011 Nobel Prize in Medicine was awarded on 3 October to Bruce Beutler and Jules Hoffmann for discoveries in innate immunity, and to Ralph Steinman for his discovery of the dendritic cell and its role in adaptive immunity. While the headline news is that Steinman's award will proceed even though he died (on 30 September) without knowing of the prize, the timing of the award can serve to remind those in the life sciences that good science – even Nobel-quality science – is not a surrogate for or predictor of subsequent commercial success.

Immune Disorders Israel

Roche Exits RNAi, Raising Questions For Stalwarts

In mid-November, in a move that seemingly came from the top, Roche opted to cease all activity in RNA interference technology, preferring to invest in other areas like next-generation antibodies and peptide therapeutics. These days RNAi company Alnylam might have some difficult questions to answer about its business development strategy - only nobody's really asking. That's because even as Roche weighs its options around divestiture of its RNAi license, technology and research sites, the future of Alnylam - and the field of RNAi more generally - is now tied solely to establishing clinical proof-of-concept for siRNA drugs, and eventually getting those drugs to market.


PCI Biotech Holding ASA

PCI Biotech Holding is developing a light-directed drug delivery system with the potential to make drug delivery more efficient and targeted, and to reduce overall toxicity. The company's technology is based on the fact that cells absorb molecules, including proteins and other biological macromolecules, drug carriers such as antibodies and nanoparticles, and some small molecules, by engulfing them with the cell membrane, in a process called endocytosis. This creates an endosome, a small "bubble" of cell membrane enclosing the absorbed molecules. For the biologically active molecules to interact with the intracellular targets, they must be released from the endosome into the cytosol in a process called "endosomal escape."

See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Mirus Bio Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arrowhead Pharmaceuticals Inc.
  • Senior Management
  • Russell R Smestad , Pres.
    Scott A Rose, VP, Fin. & Admin.
    Jon Wolff, MD, CSO
  • Contact Info
  • Roche Madison Inc.
    Phone: (608) 316-3890
    465 Science Dr.
    Ste. C
    Madison, WI 53711